Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

The discovery of epidermal growth-factor receptor (EGFR)-activating mutations and the introduction of oral EGFR tyrosine kinase inhibitors (EGFR-TKIs) have expanded the treatment options for patients with non-small cell lung cancer. The first two reversible EGFR-TKIs, erlotinib and gefitinib, are ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Valerie, Ziehr, Jacqueline, Agulnik, Mark, Johnson, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594037/
https://www.ncbi.nlm.nih.gov/pubmed/23493883
http://dx.doi.org/10.2147/OTT.S23165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594037/
https://www.ncbi.nlm.nih.gov/pubmed/23493883
http://dx.doi.org/10.2147/OTT.S23165

Ejemplares similares